This project is expected to strengthen Taiwan, China’s biopharma sector by combining the R&D resources from ITRI with key technologies and advanced manufacturing processes from Merck to cultivate high-end professionals in Taiwan, China.
Manufacturing of drugs has become increasingly complex and global, requiring us to remodel our oversight of these tasks, to improve FDA’s efficiency and reach.